Hillard Rubin

Medicine · Health Sciences

17h-index1.4kcitations33works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Erythrocyte Function and Pathophysiology(9), Virus-based gene therapy research(8), Retinal Diseases and Treatments(7), Blood groups and transfusion(5), Neonatal Health and Biochemistry(5)

Publications33 total

Sustained Correction of a Murine Model of Phenylketonuria following a Single Intravenous Administration of AAVHSC15-PAH
Molecular Therapy — Methods & Clinical Development·2020· 29 citedOpen Access
AAVHSC characterization for developing treatments for human genetic diseases of the nervous system
Molecular Genetics and Metabolism·2020
Clade F AAVHSCs cross the blood brain barrier and transduce the central nervous system in addition to peripheral tissues following intravenous administration in nonhuman primates
PLoS ONE·2019· 25 citedOpen Access
AAVHSCs target multiple cell types in the eye and have potential to treat rare retinal diseases
Investigative Ophthalmology & Visual Science·2019Open Access
Single intravenous dose of AAVHSC15 vector with human phenylalanine hydroxylase transgene results in sustained correction of phenylketonuria in the PAH mouse model
Molecular Genetics and Metabolism·2019
Stem cell-derived clade F AAVs mediate high-efficiency homologous recombination-based genome editing
Proceedings of the National Academy of Sciences·2018· 33 cited
Low Seroprevalence of Neutralizing Antibodies Targeting Two Clade F AAV in Humans
Human Gene Therapy Clinical Development·2018· 13 cited
Low Seroprevalence of Neutralizing Antibodies Targeting Two Clade F AAV in Humans
Human Gene Therapy Clinical Development·2018
Role of Myocilin Mutants and Wnt Signaling in Glaucoma
Investigative Ophthalmology & Visual Science·2015
Aurintricarboxylic acid increases yield of HSV-1 vectors
Molecular Therapy — Methods & Clinical Development·2014· 4 citedOpen Access
Inhibition of Choroidal Neovascularization in a Nonhuman Primate Model by Intravitreal Administration of an AAV2 Vector Expressing a Novel Anti-VEGF Molecule
Molecular Therapy·2010· 82 citedOpen Access
Abstract #4090: In vitro and in vivo evaluation of novel VEGF-binding proteins, sFLT01 and sFLT02
Cancer Research·2009
48 POSTER sFLT01, an anti-angiogenic protein with antitumor activity
European Journal of Cancer Supplements·2008
Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization
Gene Therapy·2008· 106 cited
Minimal Effective Dosing of a Novel Recombinant Form of VEGF Soluble Receptor 1 (sFlt-1) Delivered via AAV Vector in Inhibiting Choroidal Neovascularization in a Murine Model
Investigative Ophthalmology & Visual Science·2008
A Novel Recombinant Form of VEGF Soluble Receptor 1 (sFlt–1) Delivered via AAV Vectors Effectively Inhibits Choroidal Neovascularization in a Murine Model
Investigative Ophthalmology & Visual Science·2006
Novel Anti–VEGF Molecules for Inhibition of Angiogenesis in the Eye
Investigative Ophthalmology & Visual Science·2006
883. AAV-2 Based Gene Therapy Using Novel Anti-VEGF Molecules for Inhibition of Angiogenesis in the Eye
Molecular Therapy·2006· 1 cited
Intraocular Gene Delivery of Soluble VEGF Receptors
Investigative Ophthalmology & Visual Science·2004
Bone Marrow Stromal Cell-Mediated Gene Therapy for Hemophilia A: In Vitro Expression of Human Factor VIII with High Biological Activity Requires the Inclusion of the Proteolytic Site at Amino Acid 1648
Human Gene Therapy·1999· 33 cited
page 1 of 2Next →

Frequent Co-authors

Peter Pecháň(11), Abraham Scaria(10), Petr Jarolı́m(8), Jeff L. Ellsworth(8), Albert Seymour(7), Michael Lukason(6), Sam Wadsworth(5), Jeffery Ardinger(4), William W. Hauswirth(4), Samuel C. Wadsworth(3), A. D. Alexander(3), R. H. Yager(3), Omar L. Francone(3), Jacinthe Gingras(3), J Palek(2), Kenneth E. Sahr(2), S C Liu(2), Carlo Brugnara(2), Seth L. Alper(2), Elizabeth DuFresne(2)